This article was originally published in The Gray Sheet
U.S. shipments of the Discovery and Meridian next-generation pacemaker families are scheduled to begin May 5, following receipt of FDA approval April 30, the firm says. Approved via premarket approval application supplement to Guidant's Vigor pacemaker, the device families include single- and dual-chamber models with adaptive-rate pacing and advanced diagnostics. The devices incorporate Quick Start, Quick Check and Quick Notes features, designed to allow clinicians "to easily and quickly perform a comprehensive set of automatic tests and follow-up device operations," and provide a printout summarizing data needed for informed patient management, Guidant explains. The Discovery line also has the ability to store and display "diagnostic-quality atrial and ventricular electrograms simultaneously." The devices debuted in Europe in mid-March
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.